Sima Rafati

Summary

Publications

  1. pmc Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis
    Sima Rafati
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran 13164, Iran
    Clin Vaccine Immunol 13:1104-10. 2006
  2. ncbi request reprint Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum
    Sima Rafati
    Molecular Immunology Lab, Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 23:3716-25. 2005
  3. ncbi request reprint Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 25:4159-69. 2007
  4. doi request reprint Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran, Iran
    Exp Parasitol 128:9-17. 2011
  5. doi request reprint Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals
    Naghmeh Khoshgoo
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 26:5822-9. 2008
  6. pmc C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice
    Delaram Doroud
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    PLoS Negl Trop Dis 5:e1236. 2011
  7. ncbi request reprint Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice
    Sima Rafati
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 118:393-401. 2008
  8. ncbi request reprint Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population
    Alireza Nakhaee
    Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran
    Vet Parasitol 119:107-23. 2004
  9. doi request reprint Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis
    Amir Mizbani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 28:53-62. 2009
  10. doi request reprint Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 26:3362-70. 2008

Collaborators

  • Azam Bolhassani
  • Jafar Amani
  • Alireza Nakhaee
  • Slavica Masina
  • Mehrdad Hashemi
  • Mohammad Vasei
  • Ali H Salmanian
  • Farzin Roohvand
  • Paul Kaye
  • Iraj Sharifi
  • Azita Zadeh-Vakili
  • Annie Rochette
  • Lynn Soong
  • Alireza Firooz
  • Pascal Launois
  • Hélène Fricker-Hidalgo
  • M P Brenier-Pinchart
  • V Rodrigues
  • Haideh Darabi
  • Farnaz Zahedifard
  • Delaram Doroud
  • Yasaman Taslimi
  • Tahereh Taheri
  • Elham Mohit
  • Negar Seyed
  • Fatemeh Doustdari
  • Elham Gholami
  • Amir Mizbani
  • Majid Golkar
  • Sahar Hosseinzadeh
  • Amin Daemi
  • Abdolhossein Rouholamini Najafabadi
  • Alireza Vatanara
  • Hiva Azizi
  • Noushin Saljoughian
  • Maryam Salehi
  • Arash Memarnejadian
  • Rouholah Vahabpour
  • Narges Abdian
  • Behrooz Vaziri
  • Fatemeh Torkashvand
  • Barbara Papadopoulou
  • Arash Arashkia
  • Kayhan Azadmanesh
  • Naghmeh Khoshgoo
  • Adnene Salhi
  • Corinne Mercier
  • Marie France Cesbron-Delauw
  • Ali Khamesipour
  • Nariman Aghaei Bandbon Balenga
  • Herve Pascalis
  • Ali Eslamifar
  • Mohammad Taghikhani
  • Kazem Heidari
  • Katayoun Samimi-Rad
  • Nabiollah Namvar Asl
  • Mandana Sattari
  • Maryam Mirzaei
  • Ali Eslami Far
  • Akbar Khadem Sadegh
  • Nozhat Safaee
  • Shima Safaiyan
  • Nasir Saeedi Eslami
  • Mohammad Reza Aghasadeghi
  • Rouhollah Vahabpour
  • Aluisio Prata
  • Maribel Jiménez Alonso
  • Audrey Romano
  • Alain Dessein
  • Lucio Roberto Castellano
  • Mathieu Sertorio
  • Ferrucio Santoro
  • Christophe Chevillard
  • Helia Dessein
  • Laurent Argiro
  • Alexandre Alcais
  • Mohammad Ali Shokrgozar
  • Reza Sadaie
  • Herve Pelloux
  • Mohamed S Abdel-Latif
  • Mehdi Assmar
  • Jalal Babaie
  • Karine Musset
  • Baharak Khoshkholgh Sima
  • Fereidoun Maboudi
  • Joseph Thalhamer
  • Richard Weiss
  • Noushin Davoudi
  • Farrokh Modabber
  • Mohammad Nabi Sarbolouki

Detail Information

Publications46

  1. pmc Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis
    Sima Rafati
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran 13164, Iran
    Clin Vaccine Immunol 13:1104-10. 2006
    ..These data suggest that the amastin signature peptide could represent a relevant biomarker for the serodiagnosis of VL and, most importantly, that it could permit differentiation among the different stages of the disease...
  2. ncbi request reprint Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum
    Sima Rafati
    Molecular Immunology Lab, Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 23:3716-25. 2005
    ..We propose that the combination of DNA and recombinant protein vaccination using CPs could be instrumental to control (VL) in dogs...
  3. ncbi request reprint Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 25:4159-69. 2007
    ..This study demonstrates the potential of HSP70 in stimulating humoral responses in humans and mice and indicates there is a need to further explore and examine the value of this important molecule in the control of leishmaniasis...
  4. doi request reprint Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave, Tehran, Iran
    Exp Parasitol 128:9-17. 2011
    ..These results suggest that the development of DNA vaccines encoding VP22 fused to a target Leishmania antigen would be a promising strategy to improve immunogenicity and DNA vaccine potency...
  5. doi request reprint Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals
    Naghmeh Khoshgoo
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 26:5822-9. 2008
    ..The achieved result is highly encouraging the use of cysteine proteinases types I, II and III as vaccine candidate against visceral leishmaniasis...
  6. pmc C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice
    Delaram Doroud
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    PLoS Negl Trop Dis 5:e1236. 2011
    ..Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects...
  7. ncbi request reprint Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice
    Sima Rafati
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 118:393-401. 2008
    ..This study demonstrated that immunization with CTE display both type 1 and 2 immune signatures in experimental murine model of L. infantum infection...
  8. ncbi request reprint Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population
    Alireza Nakhaee
    Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran
    Vet Parasitol 119:107-23. 2004
    ..We showed the importance of CPB and CTE in particular as a target of immune response and their potential use for serodiagnosis in asymptomatic dogs...
  9. doi request reprint Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis
    Amir Mizbani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 28:53-62. 2009
    ..All together, these results indicate the promise of A2-expressing L. tarentolae as a safe live vaccine against visceral leishmaniasis...
  10. doi request reprint Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 26:3362-70. 2008
    ..Our study demonstrated that co-delivery of E7+Gp96 as DNA/DNA and E7+CT-gp96 as DNA/protein could be an effective approach to induce E7-specific immune responses as a potential vaccine candidate for cervical cancer...
  11. doi request reprint Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity
    Tahereh Taheri
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 126:135-45. 2010
    ..g. in differentiation and survival of amastigotes. Apparently, the SPase I expression is not essential for in vitro growth of the parasite...
  12. ncbi request reprint Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis
    Sima Rafati
    Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Mol Biochem Parasitol 135:13-20. 2004
    ..Therefore, the Leishmania signal peptidase, albeit localised intracellularly, is a significant target of the Leishmania specific immune response and highlights its potential use for serodiagnosis of cutaneous and visceral leishmaniasis...
  13. ncbi request reprint Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 24:3290-7. 2006
    ..However, our results indicated that DNA/DNA strategy developed more effective protective responses than the other two approaches and induced 81% reduction in L. major parasite load...
  14. doi request reprint Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection
    Delaram Doroud
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    J Control Release 153:154-62. 2011
    ..The nanomedical feature of this novel formulation can be applied for wide-spread use in genetic vaccination against leishmaniasis, which is currently managed only through relatively ineffectual therapeutic regimens...
  15. doi request reprint Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
    Amin Daemi
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Immunol Lett 148:117-25. 2012
    ..Altogether, our results show that comparable regions of gp96 (N-/C-terminal fragments of gp96) may have qualitatively different immunological effects in vaccine design...
  16. doi request reprint Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model
    Maryam Salehi
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Immunotherapy 4:1107-20. 2012
    ..Cervical cancer, the third most prevalent cause of cancer in women worldwide, is associated with HPVs. The critical role of E7 protein in HPV-related malignancies has designated it as a strong contender for generating vaccines against HPV...
  17. doi request reprint Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 127:637-45. 2011
    ....
  18. ncbi request reprint Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis
    Sima Rafati
    Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 103:143-51. 2003
    ..Furthermore, the asymptomatic dogs in contrast to the symptomatic cases exhibited specific lymphocyte proliferation to both crude antigens and rCPs...
  19. doi request reprint Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections
    Elham Mohit
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Mol Immunol 53:149-60. 2013
    ..Therefore, this approach suggests a combinational therapeutic strategy against cervical and other HPV-related cancers...
  20. doi request reprint Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis
    Narges Abdian
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 127:627-36. 2011
    ..Therefore, we recommend further investigations on the usage of LPG3 co-delivery with candidate antigens for vaccine development against leishmaniasis...
  21. doi request reprint Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7
    Jafar Amani
    Applied Biotechnology Research Center, Baqiyatallah Medical Science University, Tehran, Iran
    Vaccine 28:6923-9. 2010
    ..coli. The immunization was conducted in mice with purified rEIT. The results showed that this chimeric protein induced strong humoral response as well as protection against live challenges using EHEC...
  22. ncbi request reprint Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations
    Delaram Doroud
    Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    J Pharm Pharm Sci 13:320-35. 2010
    ....
  23. ncbi request reprint Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 24:2169-75. 2006
    ....
  24. ncbi request reprint Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis
    Azita Zadeh-Vakili
    Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 22:1930-40. 2004
    ....
  25. doi request reprint Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae
    Amir Mizbani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Parasitol Res 109:793-9. 2011
    ..Altogether, our results show that A2 is functional in L. tarentolae, although through an unknown mechanism, and loss of A2 has been one of the factors partly contributing to the loss of virulence of L. tarentolae...
  26. pmc In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response
    Negar Seyed
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    PLoS Negl Trop Dis 5:e1295. 2011
    ..The first step toward a peptide vaccine is epitope mapping of different proteins according to the most frequent HLA types in a population...
  27. ncbi request reprint A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers
    Sahar Hosseinzadeh
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Drug Deliv 20:190-8. 2013
    ..tar-E7. Indeed, the recombinant live vector is capable of eliciting effective humoral and cellular immune responses in mice, but however, further studies are required to increase their efficacy...
  28. ncbi request reprint Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Indian J Med Res 130:533-41. 2009
    ..The aim of the present investigation was to determine and search for serologic markers in cervical cancer patients associated with HPV...
  29. doi request reprint The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen
    Azam Bolhassani
    Pasteur Institute of Iran, Tehran, Iran
    Drug Deliv 16:196-204. 2009
    ..Therefore, this new delivery system could have promising applications in gene therapy...
  30. pmc Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis
    Noushin Saljoughian
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    PLoS Negl Trop Dis 7:e2174. 2013
    ..Altogether, these results indicate the promise of the A2-CPA-CPB(-CTE)-recombinant L. tarentolae as a safe live vaccine candidate against VL...
  31. doi request reprint Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice
    Jafar Amani
    Department of Plant Biotechnology, National Institute of Genetic Engineering and Biotechnology NIGEB, Tehran, Iran
    Plant Sci 180:620-7. 2011
    ..coli O157:H7 significantly exhibited reduced bacterial shedding. Application of transgenic plants containing trivalent immunogen is an effective tool for protection against E. coli O157:H7...
  32. doi request reprint Chemokine-based immunotherapy: delivery systems and combination therapies
    Elham Mohit
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran 13164, Iran
    Immunotherapy 4:807-40. 2012
    ..In this review, several chemokines with their role in inducing immune response against different diseases are discussed, with a major emphasis on cancer...
  33. doi request reprint Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems
    Delaram Doroud
    Quality Control Department, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
    Expert Rev Vaccines 11:69-86. 2012
    ....
  34. pmc Improvement of different vaccine delivery systems for cancer therapy
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Mol Cancer 10:3. 2011
    ..This review will focus on the utilization of different vaccine delivery systems for prevention or treatment of cancer. We will discuss their clinical applications and the future prospects for cancer vaccine development...
  35. doi request reprint Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice
    Arash Arashkia
    Hepatitis and AIDS Department NRGB Lab, Pasteur Institute of Iran, Pasteur Ave, Tehran 1316943551, Iran
    Virus Genes 40:44-52. 2010
    ....
  36. pmc Mini-chaperones: potential immuno-stimulators in vaccine design
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Hum Vaccin Immunother 9:153-61. 2013
    ..In this review, we describe the immuno-stimulatory activities of various mini-chaperones in development of different vaccine strategies (DNA-based vaccine and protein/peptide-based vaccines)...
  37. ncbi request reprint Different spectra of therapeutic vaccine development against HPV infections
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Hum Vaccin 5:671-89. 2009
    ..Human trials are the most important test for the efficacy of HPV16/18 E6 and E7 proteins as immunotherapy for cervical cancer. This review attempts to describe different therapeutic vaccinations against HPV infections...
  38. ncbi request reprint Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy
    Nariman Aghaei Bandbon Balenga
    Department of Biotechnology, Faculty of Science, University of Tehran, Tehran, Iran
    J Biotechnol 124:602-14. 2006
    ..Also higher amounts of DNA contributed to stronger Th1 response...
  39. ncbi request reprint Leishmaniasis vaccine candidates for development: a global overview
    Ali Khamesipour
    Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
    Indian J Med Res 123:423-38. 2006
    ..This is not an exhaustive review of vaccine discovery or the principles of clinical immunology underlying vaccine development...
  40. ncbi request reprint Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation
    Sima Rafati
    Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 20:2439-47. 2002
    ..Taken together, it was shown that the induced partial protection was mainly dependent on IFN-gamma producing CD8(+) T cells...
  41. doi request reprint Heat-shock proteins as powerful weapons in vaccine development
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Expert Rev Vaccines 7:1185-99. 2008
    ..Their ability in eliciting immune responses against different pathogens (parasite and virus) and their role in cancer immunity will be discussed in this review...
  42. pmc In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications
    Jafar Amani
    National Institute of Genetic Engineering and Biotechnology, Shahrak e Pajoohesh, 15th Km, Tehran Karaj Highway, Tehran, IR, Iran
    Theor Biol Med Model 6:28. 2009
    ..Among these proteins, Intimin, Tir, and EspA, which are expressed by attaching-effacing genes, are responsible for the attachment to epithelial cell that leads to lesions...
  43. ncbi request reprint Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice
    Majid Golkar
    CNRS UMR 5163 Université Joseph Fourier, UFR de Biologie, Institut Jean Roget, Campus Sante, Domaine de la Merci BP 170, 38042 Grenoble Cedex 09, France
    Vaccine 25:4301-11. 2007
    ..This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response...
  44. pmc Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis
    Herve Pascalis
    Immunologie des Leishmanioses, Institut Pasteur de le Guyane Française, Institut d Etudes Supérieures de la Guyane, Universite Antilles Guyane, Cayenne, French Guiana
    Infect Immun 71:2924-6. 2003
    ..The results suggest that CPs would be quite good candidates for a vaccine against different Leishmania species...
  45. ncbi request reprint The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women
    Majid Golkar
    CNRS UMR 5163, UFR de Biologie, Institut Jean Roget, Universite Joseph Fourier, Campus Sante, Domaine de la Merci, and Parasitology and Mycology Laboratory, Grenoble Teaching Hospital A Michallon, Grenoble Cedex 09, France
    Diagn Microbiol Infect Dis 58:419-26. 2007
    ..4% (sera collected in Iran) for sera of chronic infection. The recombinant GRA2 could thus advantageously complement previously described T. gondii antigens for the serodiagnosis of acute Toxoplasma infection...
  46. ncbi request reprint Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis
    Adnene Salhi
    Institut National de la Santé et de la Recherche Médicale U399, Faculty of Medicine, 17 Boulevard Jean Moulin, Marseille Cedex 05, France
    J Immunol 180:6139-48. 2008
    ..These observations demonstrate an important role for IL-10 in skin lesions in humans infected with L. braziliensis, and identify circulating monocytes and Tregs as principal sources of IL-10 in these patients...